What’s Next: A Growing Body of Evidence to Support Our Platform
Inhalon’s muco-trapping platform has already been proven effective in over a half dozen pathogens to date, with extensive in vitro and in vivo proof-of-concept demonstrations:
In treating RSV, Inhalon's antibodies produced a ≥ 4-log reduction in viral load in an RSV neonatal lamb model—the “gold-standard” large-animal model, since lamb lung physiology closely matches that of a human infant.
Our muco-trapping antibodies have also demonstrated activity in mouse and cotton rats infected with RSV.
The broad applicability of our muco-trapping platform was illustrated by showing the same approach could trap particles similar to the Ebola virus in human airway mucus and facilitate their rapid elimination from mouse lung airways.
We are currently undertaking preclinical development for our lead anti-RSV antibody, IN-002.
Clinical Trial Overview
Inhalon Biopharma has been awarded a contract by the U.S. Army Medical Research & Development Command to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients, with initial results expected in 2022.